CO2022003091A2 - Nuevos compuestos - Google Patents
Nuevos compuestosInfo
- Publication number
- CO2022003091A2 CO2022003091A2 CONC2022/0003091A CO2022003091A CO2022003091A2 CO 2022003091 A2 CO2022003091 A2 CO 2022003091A2 CO 2022003091 A CO2022003091 A CO 2022003091A CO 2022003091 A2 CO2022003091 A2 CO 2022003091A2
- Authority
- CO
- Colombia
- Prior art keywords
- new compounds
- present description
- compounds
- diseases
- fibrotic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201913603A GB201913603D0 (en) | 2019-09-20 | 2019-09-20 | New compounds |
| PCT/GB2020/052261 WO2021053344A1 (en) | 2019-09-20 | 2020-09-18 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022003091A2 true CO2022003091A2 (es) | 2022-04-19 |
Family
ID=68425648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0003091A CO2022003091A2 (es) | 2019-09-20 | 2022-03-17 | Nuevos compuestos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12435072B2 (https=) |
| EP (1) | EP4031240A1 (https=) |
| JP (2) | JP7771049B2 (https=) |
| KR (1) | KR20220101071A (https=) |
| CN (1) | CN114786774A (https=) |
| AU (1) | AU2020351301B2 (https=) |
| BR (1) | BR112022003130A2 (https=) |
| CA (1) | CA3152218A1 (https=) |
| CL (1) | CL2022000656A1 (https=) |
| CO (1) | CO2022003091A2 (https=) |
| GB (1) | GB201913603D0 (https=) |
| IL (1) | IL291172A (https=) |
| MX (2) | MX2022003286A (https=) |
| PH (1) | PH12022550564A1 (https=) |
| WO (1) | WO2021053344A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB2605148A (en) * | 2021-03-23 | 2022-09-28 | Vicore Pharma Ab | New compounds |
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202113583D0 (en) * | 2021-09-23 | 2021-11-10 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| MX2024000518A (es) * | 2021-07-09 | 2024-01-31 | Vicore Pharma Ab | Nuevos compuestos selectivos de angiotensina ii. |
| CA3247073A1 (en) * | 2022-04-06 | 2025-02-03 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | AT2R AGONIST |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| DE19920815A1 (de) | 1999-05-05 | 2000-11-09 | Aventis Pharma Gmbh | 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| KR100938817B1 (ko) | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| KR20150028761A (ko) * | 2011-12-16 | 2015-03-16 | 타릭스 파마슈티컬스 엘티디. | 섬유증 치료용 안지오텐신 |
| KR102230461B1 (ko) | 2013-03-15 | 2021-03-22 | 유니버시티 오브 써던 캘리포니아 | 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들 |
| EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) * | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| AR108906A1 (es) * | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
-
2019
- 2019-09-20 GB GB201913603A patent/GB201913603D0/en not_active Ceased
-
2020
- 2020-09-18 WO PCT/GB2020/052261 patent/WO2021053344A1/en not_active Ceased
- 2020-09-18 CN CN202080065335.5A patent/CN114786774A/zh active Pending
- 2020-09-18 AU AU2020351301A patent/AU2020351301B2/en active Active
- 2020-09-18 PH PH1/2022/550564A patent/PH12022550564A1/en unknown
- 2020-09-18 EP EP20780297.6A patent/EP4031240A1/en active Pending
- 2020-09-18 BR BR112022003130A patent/BR112022003130A2/pt unknown
- 2020-09-18 MX MX2022003286A patent/MX2022003286A/es unknown
- 2020-09-18 US US17/761,670 patent/US12435072B2/en active Active
- 2020-09-18 KR KR1020227008929A patent/KR20220101071A/ko active Pending
- 2020-09-18 CA CA3152218A patent/CA3152218A1/en active Pending
- 2020-09-18 JP JP2022516299A patent/JP7771049B2/ja active Active
-
2022
- 2022-03-07 IL IL291172A patent/IL291172A/en unknown
- 2022-03-17 CL CL2022000656A patent/CL2022000656A1/es unknown
- 2022-03-17 MX MX2025000262A patent/MX2025000262A/es unknown
- 2022-03-17 CO CONC2022/0003091A patent/CO2022003091A2/es unknown
-
2025
- 2025-10-02 US US19/348,124 patent/US20260028333A1/en active Pending
- 2025-11-05 JP JP2025186669A patent/JP2026041728A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020351301A1 (en) | 2022-03-17 |
| EP4031240A1 (en) | 2022-07-27 |
| JP2022549086A (ja) | 2022-11-24 |
| AU2020351301B2 (en) | 2026-02-12 |
| JP7771049B2 (ja) | 2025-11-17 |
| IL291172A (en) | 2022-05-01 |
| CN114786774A (zh) | 2022-07-22 |
| BR112022003130A2 (pt) | 2022-05-17 |
| CL2022000656A1 (es) | 2022-11-04 |
| GB201913603D0 (en) | 2019-11-06 |
| US20260028333A1 (en) | 2026-01-29 |
| KR20220101071A (ko) | 2022-07-19 |
| PH12022550564A1 (en) | 2023-03-20 |
| US20220388994A1 (en) | 2022-12-08 |
| US12435072B2 (en) | 2025-10-07 |
| CA3152218A1 (en) | 2021-03-25 |
| MX2022003286A (es) | 2022-04-12 |
| WO2021053344A1 (en) | 2021-03-25 |
| MX2025000262A (es) | 2025-02-10 |
| JP2026041728A (ja) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003091A2 (es) | Nuevos compuestos | |
| CL2023000580A1 (es) | Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| PE20181289A1 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| MX2017016908A (es) | Inhibidores de nadph oxidasa 4. | |
| PE20211698A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MX2018014758A (es) | Piridinas sustituidas con heteroarilo y metodos de uso. | |
| JOP20190115A1 (ar) | مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| MX2021001565A (es) | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). | |
| MX385960B (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). | |
| PE20121806A1 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
| PE20140105A1 (es) | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos | |
| PE20142376A1 (es) | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas | |
| PH12018501849A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| PH12018501575A1 (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| EP3867393A4 (en) | Enzymatic production of tagatose | |
| MX2021014157A (es) | Formas cristalinas de un inhibidor btk. | |
| PE20151718A1 (es) | Compuestos piridinilpirazoloquinolina | |
| PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| NZ703217A (en) | Novel cyclic depsipeptide derivatives and harmful organism control agents comprising the same | |
| CO2017003969A2 (es) | Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante | |
| PE20170119A1 (es) | Novedosas pirimidinas 2,5-sustituidas |